Management ChangeMay 6, 2026, 07:03 AM
Anavex Life Sciences Appoints Terrie Kellmeyer Interim CEO
AI Summary
Anavex Life Sciences Corp. announced the appointment of Terrie Kellmeyer, PhD, as Interim Chief Executive Officer. This follows the departure of former President and CEO Christopher Missling, PhD, on April 30, 2026, whose resignation was requested by the Board of Directors. Dr. Kellmeyer, previously Senior VP of Clinical Development and Senior Advisor, will lead the company's strategic initiatives to enhance clinical development programs. The company also expects to file a Form 12b-25 to extend the filing date for its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.
Key Highlights
- Terrie Kellmeyer, PhD, appointed Interim Chief Executive Officer.
- Former President and CEO Christopher Missling, PhD, departed on April 30, 2026.
- Dr. Missling's resignation was requested by the Board of Directors.
- Dr. Kellmeyer has nearly three decades of drug development experience.
- Company will focus on lead candidate blarcamesine in early Alzheimer's disease.
- Anavex expects to file Form 12b-25 to extend Q2 2026 Form 10-Q filing.
- Company plans a conference call for Q2 2026 financial results at a later date.